|
gptkbp:instanceOf
|
gptkb:chemical_compound
recreational drug
stimulant
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:actsOn
|
central nervous system
|
|
gptkbp:alternativeName
|
amine
heroin
methamphetamine
phenethylamine
substituted_amphetamine
|
|
gptkbp:associatedWith
|
gptkb:meth_mouth
memory loss
skin sores
weight loss
hyperactivity
violent behavior
formication
increased libido
long-term cognitive deficits
|
|
gptkbp:ATCCode
|
gptkb:N06BA01
N06BA03
|
|
gptkbp:boilingPoint
|
215 °C
|
|
gptkbp:brand
|
gptkb:Desoxyn
gptkb:Adzenys_XR-ODT
gptkb:Benzedrine
gptkb:Dynavel_XR
gptkb:Evekeo
|
|
gptkbp:CASNumber
|
300-62-9
537-46-2
|
|
gptkbp:chemicalFormula
|
C9H13N
C10H15N
|
|
gptkbp:controlledBy
|
gptkb:DEA
gptkb:UN_Single_Convention_on_Narcotic_Drugs
|
|
gptkbp:derivedFrom
|
amphetamine
|
|
gptkbp:detects
|
blood test
urine drug test
hair analysis
|
|
gptkbp:discoveredBy
|
gptkb:Lazăr_Edeleanu
|
|
gptkbp:discoveredIn
|
1887
|
|
gptkbp:drugClass
|
amphetamine
monoamine releasing agent
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
gptkb:Romania
gptkb:Nagai_Nagayoshi
|
|
gptkbp:hasInChIKey
|
KWTSXDURSIMDCE-UHFFFAOYSA-N
|
|
gptkbp:hasPotentialForAbuse
|
high
|
|
gptkbp:hasSMILES
|
CC(CC1=CC=CC=C1)NC
|
|
gptkbp:hasStreet
|
gptkb:glass
gptkb:shabu
ice
crystal
tik
|
|
gptkbp:hasUNII
|
44RAL3456C
|
|
gptkbp:improves
|
dopamine levels
norepinephrine levels
serotonin levels
|
|
gptkbp:isIllicitlyManufactured
|
true
|
|
gptkbp:isNeurotoxic
|
true
|
|
gptkbp:isomerOf
|
gptkb:dextroamphetamine
gptkb:levoamphetamine
|
|
gptkbp:isStimulant
|
true
|
|
gptkbp:isUsedRecreationally
|
true
|
|
gptkbp:IUPACName
|
gptkb:N-methyl-1-phenylpropan-2-amine
1-phenylpropan-2-amine
|
|
gptkbp:KEGGID
|
D07441
|
|
gptkbp:legalStatus
|
gptkb:Schedule_8_(Australia)
Schedule I (Canada)
Class A drug (UK)
Schedule II controlled substance (US)
Class B drug (UK)
Schedule I controlled substance (Canada)
|
|
gptkbp:mainStreet
|
speed
bennies
pep pills
uppers
|
|
gptkbp:mechanismOfAction
|
increases synaptic concentrations of dopamine and norepinephrine
|
|
gptkbp:medicalUse
|
treatment of ADHD
treatment of obesity
|
|
gptkbp:meltingPoint
|
170 °C (hydrochloride salt)
|
|
gptkbp:MeSH_ID
|
D000700
|
|
gptkbp:metabolism
|
gptkb:selegiline
amphetamine
|
|
gptkbp:molecularWeight
|
135.21 g/mol
149.24 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
3007
2900
CHEMBL1201207
CHEMBL405
10836
CHEBI:6809
DB01577
|
|
gptkbp:relatedTo
|
gptkb:ephedrine
gptkb:MDMA
gptkb:methylphenidate
gptkb:pseudoephedrine
amphetamine
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
intranasal
smoked
|
|
gptkbp:sideEffect
|
addiction
anxiety
hypertension
loss of appetite
paranoia
psychosis
increased heart rate
insomnia
|
|
gptkbp:subjectOf
|
methamphetamine epidemic
|
|
gptkbp:UNII
|
U3C098442E
|
|
gptkbp:usedFor
|
treatment of ADHD
treatment of narcolepsy
|
|
gptkbp:wasFirstSynthesizedIn
|
1893
|
|
gptkbp:bfsParent
|
gptkb:Charlie_Pace
gptkb:Junky
gptkb:IG_Farben
gptkb:Bobby_Driscoll
gptkb:Felix_Hoffmann
|
|
gptkbp:bfsLayer
|
5
|